State Street’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.1B | Buy |
15,726,193
+864,784
| +6% | +$44.7M | 0.03% | 392 |
|
|
2026
Q1 | $755M | Sell |
14,861,409
-1,504,069
| -9% | -$70.2M | 0.03% | 463 |
|
|
2025
Q4 | $483M | Sell |
16,365,478
-743,117
| -4% | -$20.2M | 0.02% | 570 |
|
|
2025
Q3 | $442M | Sell |
17,108,595
-162,036
| -0.9% | -$4.52M | 0.02% | 599 |
|
|
2025
Q2 | $476M | Sell |
17,270,631
-507,927
| -3% | -$13.4M | 0.02% | 562 |
|
|
2025
Q1 | $504M | Buy |
17,778,558
+201,322
| +1% | +$7.14M | 0.02% | 531 |
|
|
2024
Q4 | $731M | Buy |
17,577,236
+730,024
| +4% | +$34.9M | 0.03% | 458 |
|
|
2024
Q3 | $1.13B | Buy |
16,847,212
+1,823,276
| +12% | +$167M | 0.05% | 342 |
|
|
2024
Q2 | $1.78B | Buy |
15,023,936
+571,901
| +4% | +$72.4M | 0.08% | 226 |
|
|
2024
Q1 | $1.54B | Sell |
14,452,035
-171,688
| -1% | -$17.3M | 0.07% | 259 |
|
|
2023
Q4 | $1.45B | Buy |
14,623,723
+672,447
| +5% | +$56.6M | 0.07% | 260 |
|
|
2023
Q3 | $1.44B | Sell |
13,951,276
-275,951
| -2% | -$30.8M | 0.08% | 240 |
|
|
2023
Q2 | $1.73B | Buy |
14,227,227
+150,872
| +1% | +$20.1M | 0.09% | 212 |
|
|
2023
Q1 | $2.16B | Sell |
14,076,355
-224,062
| -2% | -$37M | 0.12% | 156 |
|
|
2022
Q4 | $2.57B | Sell |
14,300,417
-205,649
| -1% | -$33.6M | 0.15% | 142 |
|
|
2022
Q3 | $1.72B | Sell |
14,506,066
-260,514
| -2% | -$39.5M | 0.11% | 179 |
|
|
2022
Q2 | $2.11B | Sell |
14,766,580
-80,550
| -0.5% | -$11.5M | 0.13% | 160 |
|
|
2022
Q1 | $2.56B | Sell |
14,847,130
-16,240
| -0.1% | -$2.73M | 0.13% | 156 |
|
|
2021
Q4 | $3.77B | Buy |
14,863,370
+905,789
| +6% | +$265M | 0.18% | 106 |
|
|
2021
Q3 | $5.37B | Buy |
13,957,581
+6,632,005
| +91% | +$2.45B | 0.28% | 69 |
|
|
2021
Q2 | $1.72B | Buy |
7,325,576
+1,316,702
| +22% | +$235M | 0.09% | 210 |
|
|
2021
Q1 | $787M | Sell |
6,008,874
-15,813
| -0.3% | -$2.29M | 0.05% | 377 |
|
|
2020
Q4 | $629M | Sell |
6,024,687
-559,240
| -8% | -$56.6M | 0.04% | 419 |
|
|
2020
Q3 | $466M | Buy |
6,583,927
+556,953
| +9% | +$38.8M | 0.03% | 447 |
|
|
2020
Q2 | $387M | Buy |
6,026,974
+530,003
| +10% | +$29M | 0.03% | 492 |
|
|
2020
Q1 | $165M | Buy |
5,496,971
+87,157
| +2% | +$2.01M | 0.01% | 675 |
|
|
2019
Q4 | $106M | Buy |
5,409,814
+3,258,554
| +151% | +$57.8M | 0.01% | 1011 |
|
|
2019
Q3 | $34.2M | Buy |
2,151,260
+1,841,385
| +594% | +$27.2M | ﹤0.01% | 1703 |
|
|
2019
Q2 | $4.54M | Buy |
309,875
+7,895
| +3% | +$170K | ﹤0.01% | 2881 |
|
|
2019
Q1 | $6.14M | Buy |
+301,980
| New | +$5.6M | ﹤0.01% | 2658 |
|
Other funds holding MRNA
TP
State Street's MRNA Position: Q2 2026 in Review
State Street increased its Moderna (MRNA) stake by 5.8% in Q2 2026, buying an estimated $44.7M and bringing the position to 15,726,193 shares worth $1.1B. The position accounts for 0.03% of the portfolio, ranked #392.
State Street first reported a position in MRNA in Q1 2019 and has held it in 30 quarters since. The position peaked at $5.37B in Q3 2021. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- State Street held 15,726,193 shares of Moderna worth $1.1B as of Q2 2026.
- State Street bought 864,784 Moderna shares in Q2 2026, an estimated $44.7M.
- Moderna made up 0.03% of State Street's portfolio in Q2 2026, its #392 holding.
- State Street first reported a position in Moderna in Q1 2019 and has held it in 30 quarters since.
- State Street's Moderna position peaked at $5.37B in Q3 2021.
- 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.